(NewsDirect)
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tellsProactive the company has been granted additional Orphan DrugDesignation for PTX-100 for the treatment of T-cell lymphomas (TCL),including cutaneous TCL (CTCL). The designation from the Office ofOrphan Products Development at the US Food and Drug Administration,follows ODD for peripheral TCL (PTCL) in 2022. The latest designationbroadens the clinical-stage oncology company’s range to allTCLs.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.